Phase 1b multi-indication study of the antibody drug conjugate anetumab ravtansine in patients with mesothelin-expressing advanced or recurrent malignancies.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Journal of Clinical Oncology

• Publication date

  2018-05-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2018.36.15_SUPPL.TPS2607
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Understanding the landscape of immunotherapy in thymic epithelial tumors

  2023cites this paper
• Antibody drug conjugates: hitting the mark in pancreatic cancer?

  2023cites this paper
• The clinical terrain of immunotherapies in heterogeneous pancreatic cancer: unravelling challenges and opportunities

  2023cites this paper
• ‘Targeting’ Improved Outcomes with Antibody-Drug Conjugates in Non-Small Cell Lung Cancer—An Updated Review

  2023cites this paper
• Immunotherapy for Management of Thymic Epithelial Tumors: A Double-Edged Sword

  2022cites this paper
• The State-of-the-Art of Phase II/III Clinical Trials for Targeted Pancreatic Cancer Therapies

  2021cites this paper
• Mesothelin expression in esophageal adenocarcinoma and squamous cell carcinoma and its possible impact on future treatment strategies

  2020cites this paper
• Emerging therapeutic agents for advanced non-small cell lung cancer

  2020cites this paper
• Antibody drug conjugate development in gastrointestinal cancers: hopes and hurdles from clinical trials

  2018cites this paper